Recent Updates
Recently added Catalysts

CANA/MET

Phase 1

Healthy Volunteers | Small molecule | Other |Johnson & Johnson|Last Updated: Jul 14, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment36
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02039245Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose CombinationPHASE1 COMPLETED 12Jan 1, 2014Mar 1, 2014Apr 2, 20141 United States
NCT02039258Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With FoodPHASE1 COMPLETED 24Jan 1, 2014Mar 1, 2014Jul 14, 20141 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Plasma concentration of canagliflozin following the dose of 2 CANA/MET XR FDC tablets
Day 1, Day 7

Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.

Plasma concentration of metformin following the dose of 2 CANA/MET XR FDC tablets
Day 1, Day 7

Plasma concentrations of metformin are used to evaluate how long it stays in the body.

Plasma concentration of canagliflozin following the single dose of CANA/MET XR FDC after fed and fasted conditions
Predose, (before tablet intake) up to 72 hours afterdose

Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.

Plasma concentration of metformin following the single dose of CANA/MET XR FDC after fed and fasted conditions
Predose, up to 72 hours afterdose

Plasma concentrations of metformin are used to evaluate how long metformin stays in the body.

Secondary Endpoints
Percentage of participants with adverse events as a measure of safety and tolerability
Screening, up to Day 10 of the follow-up
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Canagliflozin/Metformin XREXPERIMENTALEach patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
Sequence ABEXPERIMENTALA single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
Sequence BAEXPERIMENTALA single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
Interventions
NameTypeDescription
CANA/MET XR FDCDRUGEach tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Must sign an informed consent document indicating they understand the purpose of the study and procedures * Must have a body mass index (BMI) of between 18 and 30 kg/m², inclusive * Must have a body weight of not less than 50 kg * Must have a blood pressure between 90 and 140 ...

Countries:United States
Unlock Eligibility Criteria